Objective: To assess the application value of combined detection of HbA2 and HbF for the screening of thalassemia among a population of childbearing age in Quanzhou, Fujian, and determine the optimal cut-off values for the region.
Methods: Capillary hemoglobin electrophoresis and genetic testing for α and β globin gene mutations were simultaneously carried out on 11 428 patients with suspected thalassemia. Statistical methods were used to analyze the distribution of various types of thalassemia and compare the performance of HbA2 and HbF measurement for the screening of various types of thalassemia. The optimal cut-off values for HbA2 and HbF were determined with the ROC curves.
Results: 4591 patients with α, β, and αβ compound thalassemia were identified by genetic testing. The most common genotypes for α and β thalassemia included --SEA/αα and β654/βN, β41-42/βN, and β17/βN. The ROC curves were drawn to compare the performance of HbA2 screening for α-, β-, αβ-compound, static α-, mild α-, and intermediate α-thalassemia, and the maximum area under the curves was 0.674, 0.984, 0.936, 0.499, 0.731, 0.956, and the optimal cut-off values for HbA2 were 2.45%, 3.25%, 3.65%, 2.95%, 2.55%, 1.75%, respectively.
Conclusion: HbA2 is an efficient indicator for identifying intermediate types of α-, β-, and αβ compound thalassemia. The combination of HbA2 and HbF measurement can effectively detect carriers for β-thalassemia mutations.
Download full-text PDF |
Source |
|---|
Publication Analysis
Top Keywords
Similar Publications
False HbA value due to a rare variant of hemoglobin Petie Salpetriere coinherited with alpha thalassemia.
Adv Lab Med
December 2024
Department of Laboratory Service, Área de Gestión Sanitaria Norte de Huelva, Hospital de Riotinto, Minas de Riotinto, Huelva, Spain.
Objectives: To describe a variant hemoglobin that interferes with HbA analysis by cation exchange HPLC.
Case Presentation: A 78 years-old Spanish male patient visited the Internal Medicine Clinic for a routine check-up, with HbA included to screen for diabetes. He had suffered hypertension and dyslipidemia, and the patient had no previous symptoms suggestive of diabetes such as hyperglycemia, weight loss, polydipsia, polyuria or tiredness.
Standardization of hemoglobin A and hemoglobin F: Achievements and perspectives.
Clin Chim Acta
February 2025
EC, Joint Research Centre, Directorate F - Health and Food, Reference Materials Unit, Geel, Belgium.
The establishment of reference systems for the standardization of hemoglobin A (HbA) and fetal hemoglobin (HbF), both critical for improving diagnostic accuracy in conditions such as β-thalassemia and sickle cell disease, are described. Efforts were led by the IFCC and other groups to address and reduce the variability in laboratory measurements of these hemoglobins. This document outlines the production of certified reference materials (CRMs) for HbA and the development of a reference measurement procedure using isotope dilution mass spectrometry.
View Article and Find Full Text PDFEstimation of HbA1c Levels in Transfusion-Dependent Thalassemia Patients in Comparison With Normal Healthy Individuals.
Cureus
November 2024
Internal Medicine, Sri Guru Ram Das Institute of Medical Sciences & Research, Amritsar, IND.
Introduction HbA1c values used for diagnosing and treating diabetes can be affected by factors such as red blood cell lifespan, hemolysis, red cell transfusion, and the presence of minor Hb species like HbA2 and HBF in hemoglobinopathies like sickle cell disease, homozygous HbC disease, HbSC disease, and β-thalassemia. This study aims to compare HbA1c levels in transfusion-dependent thalassemia (TDT) patients and healthy individuals. Materials and methods This is a cross-sectional comparative study.
View Article and Find Full Text PDFGenetic Modifiers of Hemoglobin Expression from a Clinical Perspective in Hemoglobinopathy Patients with Beta Thalassemia and Sickle Cell Disease.
Int J Mol Sci
November 2024
Center of Expertise in Hemoglobinopathies and Their Complications, Thalassemia and Sickle Cell Disease Unit, Hippokration General Hospital, 41221 Athens, Greece.
Article Synopsis
- Hemoglobinopathies, such as β-thalassemia and sickle cell disease, are inherited disorders caused by genetic mutations affecting the production and structure of hemoglobin, leading to severe anemia in β-thalassemia and distorted red blood cells in SCD.
- Recent advancements in gene therapy and gene editing show promise, but there is still a need to understand the mechanisms regulating hemoglobin production and to develop new, targeted treatments.
- The review focuses on the complex molecular pathways that impact hemoglobin expression, discusses potential therapeutic strategies, and highlights drugs and interventions designed to restore normal hemoglobin function in affected patients.
Haemoglobin types and variant interference with HbA1c and its association with uncontrolled HbA1c in type 2 diabetes mellitus.
BMC Res Notes
November 2024
Department of Biomedical Science and Technology, School of Public Health Maseno University, Private Bag, Maseno, Kenya.
Diabetes mellitus is among the leading global health concerns, causing over 1.5 million deaths alongside other significant comorbidities and complications. Conventional diagnosis involves estimating fasting, random blood glucose levels and glucose tolerance test.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!